Influence of efflux transporters on drug metabolism: theoretical approach for bioavailability and clearance prediction.
Cytochrome P450 enzymes and efflux transporters, expressed in the intestine and/or in the liver, play important roles in drug clearance and oral bioavailability. The relative contribution of transporters and enzymes in drug metabolism is still controversial. Some antiepileptic drugs, such as carbamazepine, phenytoin and phenobarbital (phenobarbitone), show time-dependent and dose-dependent pharmacokinetics due to their inductive effect on both efflux transporters and enzymes. However, steady-state plasma drug concentrations for each antiepileptic drug do not relate to oral daily dose in the same way, with decreased or increased apparent clearance according to the drug. A multicompartment pharmacokinetic model was developed in order to explain these different behaviours using a single mechanism of inductive action. The key for solving these apparent dissimilarities was to consider in the model the unique physiological connection that intestine, liver and bloodstream have. Efflux transporters not only enhance enzymatic competition in relation to first-order processes, but also change the predominance of some elimination routes. For instance, the carbamazepine-10,11-epoxide formation increases at the expense of other carbamazepine metabolites, enhancing both the systemic and presystemic elimination of parent drug. Conversely, the major hepatic metabolism of phenytoin diminishes in favour of its minor intestinal elimination, decreasing the total drug clearance.
Department of Pharmaceutical Science, Faculty of Chemistry, University of the Republic, Montevideo, Uruguay. pfagioli@fq.edu.uy
Pietro
P
Fagiolino
Marta
M
Vázquez
Rosa
R
Eiraldi
Cecilia
C
Maldonado
Alejandro
A
Scaramelli
D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001682:Biological Availability; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D006801:Humans; D008658:Inactivation, Metabolic; D007413:Intestinal Mucosa / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000378:metabolism*; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D008962:Models, Theoretical
D000927:Anticonvulsants; D026901:Membrane Transport Proteins; D003577:Cytochrome P-450 Enzyme System
Res Commun Chem Pathol Pharmacol. 1987 Nov;58(2):269-72
3423424
J Pharmacol Exp Ther. 1975 Jan;192(1):224-35
235636
J Clin Pharmacol. 1985 Jan-Feb;25(1):51-8
3973064
J Pharm Sci. 1988 Sep;77(9):768-70
3225771
J Clin Pharmacol. 1979 May-Jun;19(5-6):282-9
469023
Epilepsia. 1976 Dec;17(4):481-5
826397
Epilepsia. 1995;36 Suppl 5:S8-13
8806399
Pharmacol Rev. 2006 Jun;58(2):244-58
16714487
Clin Exp Pharmacol Physiol. 1976 May-Jun;3(3):217-24
975617
Ther Drug Monit. 1985;7(3):283-9
4049465
Clin Pharmacokinet. 2006;45(5):433-48
16640451
Epilepsy Res. 1996 Jul;24(3):163-72
8832192
Curr Neurovasc Res. 2008 May;5(2):82-92
18473823
Eur J Drug Metab Pharmacokinet. 2003 Apr-Jun;28(2):147-53
12877574
J Pharmacol Exp Ther. 2003 Jul;306(1):124-31
12663688
Epilepsia. 2003 Jul;44(7):923-9
12823575
Nephron Physiol. 2006;103(3):p97-106
16554667
Clin Pharmacol Ther. 2004 Sep;76(3):192-200
15371980
Clin Pharmacol Ther. 2004 Mar;75(3):172-83
15001968
Pharmacogenetics. 2003 Sep;13(9):565-75
12972955
Eur J Drug Metab Pharmacokinet. 2004 Jan-Mar;29(1):43-9
15151170
Clin Pharmacokinet. 2007;46(4):271-9
17375979